Protein Information

ID 3207
Name ChREBP
Synonyms CHREBP; Mlx interactor; Carbohydrate response element binding protein; MIO; MLX interacting protein like; MLXIPL; MONDOB; Mondo family member B…

Compound Information

ID 1708
Name ACC
CAS 1-aminocyclopropanecarboxylic acid

Reference

PubMed Abstract RScore(About this table)
19727214 Huo M, Zang HL, Zhang DJ, Wang B, Wu J, Zhang XY, Chen LH, Li J, Yang JC, Guan YF: [Role of increased activity of carbohydrate response element binding protein in excessive lipid accumulation in the liver of type 2 diabetic db/db mouse]. Beijing Da Xue Xue Bao. 2009 Jun 18;41(3):307-12.
OBJECTIVE: To study the role of the carbohydrate response element binding protein (ChREBP) in excessive lipid deposition in the liver of db/db mouse. METHODS: The deposition of neutral lipids in the liver was evaluated by Oil Red O staining. Immunohistochemical assay was utilized to determine the localization of ChREBP protein expression in mouse liver. The expressions of ChREBP and its target genes including acetyl-coenzyme A carboxylase 1 (Acc-1), fatty acid synthase (Fas), glycerol-3-phosphate acyltransferase (Gpat) were analyzed by Real-time PCR and Western blot. RESULTS: Significant lipid droplet deposition was detected in the livers of db/db mice. ChREBP was diffusely expressed in heptocytes with relative higher expression levels around portal and central veins. ChREBP was predominantly located in the cytosol in non-diabetic db/m mice, but was translocated to the nucleus in db/db mice. Nuclear ChREBP protein levels were 8.2-fold higher in db/db mice than in db/m mice (P <0.01). In contrast, another lipogenic transcription factor, sterol regulatory element binding protein-1 (SREBP-1), remained unchanged. Consistent with increased nuclear ChREBP levels, expressions of ChREBP target genes involved in lipogenesis including Acc-1, Fas and Gpat were upregulated by 2-fold (P <0.05),1.7-fold (P <0.05) and 4.2-fold (P <0.05), respectively, in db/db mice. CONCLUSION: The db/db mouse exhibits significantly higher liver ChREBP activity, which may be associated with the development of hepatic steatosis frequently occurring in type 2 diabetes. Targeting ChREBP might represent a new intervention strategy for fatty liver.
10(0,0,0,10)